Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


CONJUGATE OR COMPLEX OF MONOCLONAL OR POLYCLONAL ANTIBODY, IMMUNOGLOBULIN, OR FRAGMENT THEREOF WITH NONIMMUNOGLOBULIN MATERIAL

Subclass of:

424 - Drug, bio-affecting and body treating compositions

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424179100 Conjugated via claimed linking group, bond, chelating agent, or coupling agent (e.g., conjugated to proteinaceous toxin via claimed linking group, bond, coupling agent, etc.) 109
424183100 Conjugated to proteinaceous toxin or fragment thereof (e.g., conjugated to diphtheria toxin, Pseudomonas exotoxin, ricin, gelonin, abrin, etc.) 23
424182100 Conjugate includes potentiator; or composition comprising conjugate includes potentiator 4
20130028920STABILIZED ANTIBODY PREPARATIONS AND USES THEREOF - The present invention is directed to stabilized intact antibody formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing an intact antibody in a liquid carrier.01-31-2013
20120189645Compositions and methods to treat and control tumors - The present application is directed to non-coding RNA motifs that are used in conjunction with an antigen or without an antigen to induce, enhance or modulate an immune response that compromises a B cell and a T cell component.07-26-2012
20090324622ANTIBODY VACCINE CONJUGATES AND USES THEREFOR - The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (βhCG) antigen linked to an anti-mannose receptor (MR) antibody.12-31-2009
20120039916NOVEL VACCINE ADJUVANTS BASED ON TARGETING ADJUVANTS TO ANTIBODIES DIRECTLY TO ANTIGEN-PRESENTING CELLS - Compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist; and a pharmaceutically acceptable carrier are disclosed herein. The conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation.02-16-2012
Entries
DocumentTitleDate
20110177102TARGETED DOUBLE STRANDED RNA MEDIATED CELL KILLING - A method of killing a specific target cell/tissue is disclosed. The method comprises exposing the specific target cell/tissue to a composition-of-matter which comprises a double stranded RNA molecule associated with a targeting moiety selected capable of targeting to the specific target cell/tissue, thereby killing the specific target cell/tissue.07-21-2011
20090123485Antigen Antibody Complexes as HIV-1 Vaccines - The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic antibody-antigen complexes which are formulated into the vaccines of the present invention.05-14-2009
20090202571Bioreductively-activated prodrugs - A compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: —Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a benzoquinone, naphthoquinone or fused heterocyloquinone; -R1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; -R2 is a glycoside, OH, optionally substituted alkyl, optionally substituted alkoxy, C08-13-2009
20100062007MULTI-MODAL CANCER THERAPY USING VIRAL HITCH-HIKING - The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus (NDV), a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell and an immunocytokine. Also encompassed by the present invention are polynucleotides encoding the aforementioned antibody fusion protein as well as tumor-unspecific key cells or dendritic cells bound by the antibody fusion protein. Moreover, the present invention relates to a method of treating a tumor in a subject comprising administering to the said subject the antibody fusion protein, the tumor-unspecific T cell, the dendritic cell or the polynucleotide of the invention. Preferably, the said tumor is a solid tumor.03-11-2010
20100055115COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY - This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cell, methods of production, and kits.03-04-2010
20090117135VACCINE COMPRISING AN ANTIGEN CONJUGATED TO LOW VALENCY ANTI-CD40 OR ANTI-CD28 ANTIBODIES - We describe a conjugate comprising an antibody and antigen wherein said conjugate has low antibody valency and including methods to prepare said conjugate.05-07-2009
20110195077METHODS AND COMPOSITIONS USING FGF23 FUSION PPOLYPEPTIDES - The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23), or a functionally active variant or derivative thereof; and a modified Fc fragment, or a functionally active variant or derivative thereof. In various embodiments of the fusion polypeptides, FGF23 has mutations which decrease aggregation and protease-mediated cleavage.08-11-2011
20090191224Nucleolin-Mediated Cancer Diagnostics and Therapy - The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.07-30-2009
20090191222Metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression - This disclosure characterizes the function and the expression of the human protein encoded by tm9sf4. The protein is highly expressed in malignant tumor cells and therefore is a novel marker for malignancy. Moreover, the protein is involved in the phagocytotic character of tumor cells. This disclosure provides methods and tools to diagnose and follow up malignancy of tumors. Furthermore, means to inhibit phagocytotic character of tumor cells as well as means to treat cancer are provided.07-30-2009
20100158927ANTIBODIES, METHODS AND KITS FOR DIAGNOSING AND TREATING MELANOMA - A method of diagnosing melanoma and antibodies capable of same are disclosed. The method comprises contacting a cell of the subject with an antibody comprising an antigen recognition domain capable of binding to an MHC-I molecule being complexed with a tyrosinase peptide, wherein the antibody does not bind the MHC-I in the absence of the complexed peptide, and wherein the antibody does not bind the peptide in an absence of the MHC, under conditions which allow immunocomplex formation, wherein a presence of the immunocomplex or level thereof is indicative of the melanoma. Methods for treating melanoma and antibodies capable of same are also disclosed. Pharmaceutical compositions comprising antibodies are also disclosed.06-24-2010
20100150949METHODS AND COMPOSITIONS FOR MODULATING PROLINE LEVELS - Methods and compositions for modulating amino acid levels in a subject are provided herein.06-17-2010
20100119528Transport of Biologically Active Molecules into a Cell, Mitochondrion, or Nucleus - Novel carrier peptides are described, as well as methods of using the carrier peptides to transport biologically active molecules into a cell, mitochondrion, or nucleus, e.g., by formation of a complex of the carrier peptide non-covalently bound to a biologically active molecule.05-13-2010
20120183566Aldehyde-Tagged Immunoglobulin Polypeptides and Methods of Use Thereof - The present disclosure provides aldehyde-tagged immunoglobulin (Ig) polypeptides that can be converted by a formylglycine-generating enzyme to produce a 2-formylglycine (FGly)-modified Ig polypeptide. An FGly-modified Ig polypeptide can be covalently and site-specifically bound to a moiety of interest to provide an Ig conjugate. The disclosure also encompasses methods of production of such aldehyde-tagged Ig polypeptides, FGly-modified Ig polypeptides, and Ig conjugates, as well as methods of use of same.07-19-2012
20130034572COMPOSITIONS AND METHODS FOR BRAIN DELIVERY OF ANALGESIC PEPTIDES - The present invention relates to non-invasive brain delivery technology for centrally-acting analgesic peptides. Specifically, the invention is directed to compounds comprising an antibody or fragment thereof capable of transmigrating across the blood brain barrier (BBB) and an analgesic peptide. Compositions and methods of using the compounds or compositions are also provided.02-07-2013
20130084302Methods of binding TNF-alpha using Anti-TNF-alpha antibody fragment-polymer conjugates - Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α04-04-2013
20090155290Antigen - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.06-18-2009
20090155289FURIN-CLEAVABLE PEPTIDE LINKERS FOR DRUG-LIGAND CONJUGATES - Disclosed are certain peptide linkers for conjugating drugs to ligands, and the resulting drug-linker-ligand molecules and compositions thereof. The conjugated molecules useful for the targeted delivery of drugs to the desired cells, and allow for the intracellular release of the drug in cases where the targeted antigen is internalized via the trans Golgi network and not the lysosomal pathway.06-18-2009
20100104588SERUM ALBUMIN BINDING PEPTIDES FOR TUMOR TARGETING - Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.04-29-2010
20130039931Antibodies Against A Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof - The present application provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens, and uses thereof.02-14-2013
20100143388Antibody Composition-Producing Cell - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.06-10-2010
20100092494Composition and method for facilitating the internalization of a therapeutic agent into a cell - The present invention is a composition and method for facilitating the internalization of a therapeutic agent into a cell. Specifically, the invention relates to the use of the extracellular domain of basigin-2, cyclophilin, or anti-basigin-2 antibody or antibody fragment as a delivery moiety for internalization of a therape.04-15-2010
20130028917PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.01-31-2013
20090311274NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 238P1B2 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization.12-17-2009
20090304717Immuno-RNA-Constructs - Subject of the invention is a compound, consisting of a targeting moiety which specifically binds to a disease related cell surface marker, a nucleic acid which specifically induces cell death and a linker, wherein the linker covalently links the targeting moiety to the nucleic acid. Subject of the invention are also medicaments comprising the compound and their use as a medicament for the treatment of diseases, including proliferative diseases.12-10-2009
20090041790Methods for treating cardiovascular disease using a soluble CTLA4 molecule - The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.02-12-2009
20130071413TARGETED IMMUNE CONJUGATES - Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of immunogens to the reticuloendothelial system via non-circulating lymphoid cells are provided.03-21-2013
20130071412METHODS AND COMPOSITIONS FOR STABLE LIQUID DRUG FORMULATIONS - The invention features a powdered composition including a pharmaceutically active compound and a protein or a hydrolyzed protein. In particular, the powdered composition forms a stable solution or dispersion suitable for oral administration in which the protein or the hydrolyzed protein is bound to the pharmaceutically active compound. The invention also provides a method of administering the composition, such as to a patient with dysphasia; liquid or semi-solid formulations of the composition; methods for preparing the composition; and kits including the composition.03-21-2013
20100008938SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS - There are provided amphiphilic biodegradable copolymers comprising a hydrophilic backbone with pendant aliphatic groups as the hydrophobic component. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors that are capable of solubilizing insoluble organic compounds and disrupting viral coat proteins. The polymers optionally feature reactive functional groups that provide attachment points for antibodies, ligands, and other targeting moieties which mediate adherence of the aggregate to a viral target.01-14-2010
20130058962Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein - Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant heteromultimeric neutralizing binding protein including two or multiple binding regions, such that the binding regions are not identical, and each binding region specifically binds a non-overlapping portion of the disease agent, thereby treating the subject for exposure to the disease agent. In a related embodiment, the heteromultimeric neutralizing binding protein includes two or multiple binding regions that neutralize a plurality of disease agents. In certain embodiments, the disease agent includes a bacterium, a bacterial protein, a virus, a viral protein, a cancer cell, and a protein or molecule produced therefrom. In certain embodiments, the disease agent is a plurality of different disease agents.03-07-2013
20110014216Drug Transfer Based on Coenzyme A and Acyl Carrier Protein - The invention relates to coenzyme A (CoA) type compounds carrying one or more drug entities and optionally a label detectable by a fluorescence detector, magnetic resonance imaging (MRI), positron emission tomography (PET) or scintigraphy, and/or a functional group which can be transformed into a drug or a detectable label. The invention further relates to a molecular shuttle which is a fusion protein comprising a proteinaceous binding entity directed to a target and an acyl carrier protein (ACP) or a fragment thereof, and carrying one or more drug entities. The proteinaceous binding entity is designed to bind to a target structure in vitro or in vivo, for example a cellular receptor.01-20-2011
20120189644ANTI-MESOTHELIN IMMUNOCONJUGATES AND USES THEREFOR - The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors. The immunoconjugates comprise antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.07-26-2012
20120225088COMPOSITIONS AND METHODS FOR TREATING CANCER AND OTHER DISEASES - Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity. Such improvements also include stability to serum nucleases, reduced binding to a soluble form of the target molecule, increased avidity, affinity or specificity to the target molecule on a cell surface, increased lifetime in circulation, or any combination of the foregoing. Improvements are provided by truncation, multimerization, including at least one non-natural nucleic acid, adding a 3′ or 5′ polyethylene glycol, or any combination thereof. Aptamers for treatment of autoimmune diseases are also provided.09-06-2012
20090028883Novel P-selectin Ligand Protein - A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.01-29-2009
20100086558Protein Having Prolyl Oligopeptidase Activity, Nucleic Acid Encoding Same and Method for Producing and Using Same - Proteins isolated from 04-08-2010
20100086559POLYPEPTIDE FORMULATION - The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.04-08-2010
20130164310ANTI-DIABETIC COMPOUNDS - The present invention provides a composition of the formula: [FGF21-106-27-2013
20080305119Modified Bacteriophage Vectors and Uses Thereof - Provided herein are modified phage surface polypeptides, phages with modified surface polypeptides, nucleic acids that encode the modified surface polypeptides, and related vectors and phages comprising the vectors. The provided phage surface polypeptides optionally comprise one or more modifications, including, for example, one or more modifications to enhance targeting to an antigen-presenting cell and one or more modifications that destabilize a viral capsid. Further provided herein are methods of making a lambda phage with a modified surface polypeptide and methods of making a lambda phage with a plurality of modified surface polypeptides. Also provided herein are antigen delivery systems comprising the modified phages of the invention and methods of promoting an antigenic response in a subject by administering to the subject the antigen delivery system of the invention, alone or in combination with other immunization modalities.12-11-2008
20120237531TOPOISOMERASE INHIBITORS - The invention provides compounds of formula I: (I) wherein A, B, W, Y, Z, R09-20-2012
20120269829Inhibitors of Phosphatase and Tensin Homolog (PTEN) Compositions, Uses and Methods - Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease.10-25-2012
20090285838USE OF SOLUBLE CD164 IN INFLAMMATION AND AUTOIMMUNE DISORDERS - The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of human CD164, in particular for treating inflammatory and/or autoimmune disorders.11-19-2009
20110280890PRODRUGS OF CC-1065 ANALOGS - The present invention provides prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group containing a sulfonic acid containing phenyl carbamate, in which the protecting group confers enhanced water solubility upon the prodrug, and in which the prodrug also has a moiety, such as a sulfide or a disulfide, that can conjugate to a cell binding reagent such as an antibody, and for the therapeutic use of such prodrug and conjugates, and for processes for preparing such prodrugs and conjugates.11-17-2011
20110280889HIGH AFFINITY T CELL RECEPTOR AND USE THEREOF - The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.11-17-2011
20090041789Monoclonal Antibodies and Single Chain Antibody Fragments Against Cell-Surface Prostate Specific Membrane Antigen - Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.02-12-2009
20090291092TREATMENT OF MITOCHONDRIAL DISEASES WITH AN ERYTHROPOIETIN MIMETIC - Methods of treating mitochondrial disorders that are not respiratory chain disorders using compositions comprising EPO mimetic compounds or compounds capable of increasing endogenous EPO levels or stimulating erythropoiesis are disclosed. Methods of treating Friedreich's ataxia, Leigh's syndrome, or other disorders by increasing the expression of frataxin with an EPO mimetic compound or a compound capable of increasing endogenous EPO levels or stimulating erythropoiesis are also disclosed.11-26-2009
20100266620Immunoconjugates for treatment of infectious diseases - The present invention features immunoconjugates which comprise therapeutic agents coupled to antibodies that specifically recognize pathogen surface antigens. These immunoconjugates can be used to treat or prevent infectious diseases. Upon administration of an immunoconjugate of the present invention to an infected host, the immunoconjugate binds to a specific antigen on the surface of the targeted pathogen (e.g., virus). As the pathogen enters the host cells, the therapeutic agent(s) in the immunoconjugate destroys the infected host cells (and, preferably, the bound pathogen), thereby preventing the replication and transmission of the pathogen. In one embodiment, the immunoconjugates of the present invention specifically recognize surface/envelope antigens of the following viruses: HIV, HBV, HCV, EBV, influenza virus, and SARS associated coronavirus.10-21-2010
20100015165Two Step Miniemulsion Process - The present invention is directed to a method of producing nanoparticles and nanoparticles obtainable by that method. The invention further relates to a pharmaceutical composition, comprising said nanoparticles and the use of the nanoparticles for the treatment of diseases and conditions, requiring a pharmaceutical agent to cross one or more physiological barriers.01-21-2010
20100150950HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to CD70 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human CD70. In certain embodiments, the antibodies are capable of being internalized into CD70-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD70, as well as methods for treating cancers, such as renal cancer and lymphomas, using an anti-CD7Q antibody of this disclosure.06-17-2010
20100255013GLYCOPROTEIN COMPOSITIONS - The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.10-07-2010
20120288511GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are glucagon analogs comprising a modified amino acid sequence of native human glucagon (SEQ ID NO: 2) that exhibit activity at the glucagon receptor, activity at the GLP-I receptor, or activity at each of the glucagon receptor and the GLP-I receptor. In some embodiments, the glucagon analog exhibits at least 100% or more of the activity of native glucagon at the glucagon receptor and/or at least 100% or more of the activity of native GLP-I at the GLP-I receptor. In some embodiments, the glucagon analog has an EC50 at the GLP-I receptor which is within 50-fold or less than the EC50 at the glucagon receptor. In some embodiments, the glucagon analog has an EC50 at the GLP-I receptor which is two- to ten-fold greater than the EC50 at the glucagon receptor. Related conjugates, dimers and multimers, and pharmaceutical compositions, and uses thereof, are further provided.11-15-2012
20090324619Immunogenic Protein Carrier Containing An Antigen Presenting Cell Binding Domain and A Cysteine-Rich Domain - A protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain. Also described herein is an immunoconjugate containing the protein carrier with an antigen conjugated to multiple cysteine residues in the cysteine-rich domain, and an immune composition containing the immunoconjugate and an adjuvant, as well as their uses in eliciting immune responses.12-31-2009
20110287032NOVEL CTLA4-IG IMMUNOADHESINS - The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.11-24-2011
20110287035METHOD AND COMPOSITION FOR HYPERTHERMALLY TREATING CELLS - A method and composition for hyperthermally diagnosing and monitoring treatment of cells in an animal with photoacoustic sound and nanoparticles. The heat (temperature) and photoacoustic sound wave production inside the target tissue is measured. The desired temperature is achieved using a laser and photoacoustic imaging technique. Hyperthermia treatment of tissue in a target site applies a heat source to kill cells without protein denaturation. The method introduces an encapsulated dye that is released at a selected temperature in the target site to indicate that a threshold temperature has been reached to hyperthermally treat the tissue. In one embodiment, the composition releases the dye at a temperature of 42° C. to 56° C., and preferably about 45° C. to 49° C. The composition which can be a liposome composition encapsulating the dye can be introduced to the bloodstream of the patient to flow through the target site.11-24-2011
20110287034THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM CELLS - Genes that are deregulated in cancer stem cells (e.g., melanoma stem cells) are disclosed. Methods which involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes are used to treat individuals having melanoma. Cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma.11-24-2011
20110287033USE OF FERRITIN TO TREAT IRON DISORDERS - Methods and compositions for treating an iron disorder in a patient are presented, including methods for delivering a therapeutically effective amount of iron to the brain. Iron disorders that may be treated by these methods include iron deficiency disorders and iron overload disorders. A recombinant yeast expressing human H-ferritin and a composition for treating an iron disorder comprising this recombinant yeast are also presented.11-24-2011
20090280133PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF - Disclosed are compounds of Formula I effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.11-12-2009
20110165180Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses - The invention relates to the use of a polypeptide that comprises i) a first portion comprising the part of human Fc that binds to CD64, and ii) a second portion comprising one or more heterologous T cell epitopes for stimulating a cytotoxic T cell response. The polypeptide may be an antibody that may be used to stimulate a cytotoxic T cell response against pathogens and tumour cells in patients in need of such treatment.07-07-2011
20100255012RECOMBINANT FUCOSE MODIFIED MONOVALENT HALF-ANTIBODIES OBTAINED BY MOLECULAR ENGINEERING - Glycosylated monovalent antibodies binding to selected antigens with a low or lacking fucose content, which are capable of inducing antibody dependent cellular cytotoxicity (ADCC) on cells expressing the selected antigens in the presence of effector cells, methods for producing the monovalent antibodies, pharmaceutical compositions comprising such monovalent antibodies and use thereof for different diagnostic and therapeutic applications.10-07-2010
20090068204Morinda citrifolia Based Formulations for Regulating T cell Immunomodulation in Neonatal Stock Animals - Both liquid and dry form 03-12-2009
20090035323IMMUNE RESPONSE MODIFIER CONJUGATES - The present invention provides IRM conjugates that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety in which the covalent link does not depend on UV irradiation.02-05-2009
20100034836COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND ALLEVIATION OF TUMOR - The present invention is directed to methods of determining the presence of certain tumor-associated kinase polypeptides in a biological sample, and to compositions useful for the diagnosis and treatment of tumors in mammals02-11-2010
20090191223Peptides that selectively home to heart vasculature and related conjugates and methods - The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof.07-30-2009
20090098147Antibody fragment-polymer conjugates and uses of same - Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α04-16-2009
20100111976TARGETED BIOCIDES - The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense.05-06-2010
20100111977Methods and compositions for treatment of myotonic dystrophy - In certain embodiments, the present invention provides compositions and methods for treating myotonic dystrophy.05-06-2010
20090142360USE OF FERRITIN TO TREAT IRON DEFICIENCY DISORDERS - The present inventors have demonstrated the presence of H-ferritin receptors on endothelial cells in culture and on rat brain rat brain microvasculature, identifying H-ferritin as a means for transporting iron across the blood brain barrier. The present invention provides a method for treating an iron deficiency disorder in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a ferritin-iron complex. In an embodiment of the invention, the ferritin-iron complex comprises H-ferritin. In another embodiment, the iron deficiency disorder comprises an iron deficiency in the brain. The present invention also provides a method for delivering iron to the brain, comprising administering iron in the form of a ferritin-iron complex to a patient, whereby said iron is transported across the blood-brain barrier and delivered to the brain; a method for using H-ferritin as a targeting moiety, comprising attaching H-ferritin to a liposome, whereby said liposome is targeted to the brain and/or cells within the brain; and a method for treating an iron overload disorder in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a multi subunit ferritin complex, wherein said multi subunit ferritin complex is at less than 100% iron binding capacity.06-04-2009
20100215671Combination Therapy With Antibody-Drug Conjugates - Methods for the treatment of Hodgkin's lymphoma comprising administering both a chemotherapeutic regimen and an antibody-drug conjugate compound to a subject in need thereof are provided.08-26-2010
20110123553Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination - The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.05-26-2011
20100098716RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO - A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.04-22-2010
20110200624NOVEL PEPTIDES FOR USE IN TRANSFECTION - Novel peptides derived from antibody complementarity determining regions (CDRs) that enhance delivery of macromolecules into cells, particularly when used in combination with cationic lipids, are provided. The peptides can be combined with cationic lipids, and compositions of cationic lipids associated with enhancer elements, to provide reagents that can complex with macromolecules such as nucleic acids, proteins and peptides and permit introduction of these macromolecules into a variety of cells and tissues in vitro or in vivo with greatly enhanced efficiency compared to other lipid-based reagents. Methods for delivering macromolecules into target cells and tissues using the lipids and enhancer elements are provided.08-18-2011
20100080815MN Gene and Protein - A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression.04-01-2010
20090186040DOSING METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-Ig FUSION PROTEIN SUCH AS ATACICEPT - In various embodiments, the present invention provides methods, compositions, dosing, and administration schedules for treatment of autoimmune diseases, including systemic erythematosus (SLE), for example, comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule such as atacicept. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BLyS and APRIL, in particular the use of multiple administrations of the fusion molecule at relatively low dose over the course of the treatment.07-23-2009
20120107331GEMM RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GEMM RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GEMM RIBOSWITCHES - Disclosed is the crystal structure of a GEMM riboswitch from 05-03-2012
20090258029Heparin Prodrugs and Drug Delivery Stents Formed Therefrom - A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.10-15-2009
20110200622POLYPEPTIDE SPECIFICALLY BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR, FUSION PROTEIN INCLUDING POLYPEPTIDE, AND METHODS THEREFOR - A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.08-18-2011
20090142359Antibody-induced apoptosis - Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.06-04-2009
20090285841ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOF - This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.11-19-2009
20090291091USE OF THE GLOBULAR DOMAIN OF ACRP30 FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF THROMBOSIS-RELATED DISEASES - It is the object of the present invention to provide novel means for the treatment and/or prevention of thrombosis, tumor implantation, tumor seeding and metastasis. More specifically, the present invention relates to the use of a polypeptide comprising the globular head of Acrp30 for the manufacture of a medicament for treatment and/or prevention of thrombosis-related disorder, an hypertensive disorder of the pregnancy, tumor implantation, tumor seeding and metastasis.11-26-2009
20090274710TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS - Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases.11-05-2009
20090274711LEVELS OF BLyS/APRIL HETEROTRIMERS IN SERUM AND USE IN DIAGNOSTIC METHODS - The present invention provides a method of measuring the levels of BLyS/APRIL heterotrimers (HT) in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with HT antagonists, either singly or in combination with other immune suppressive drugs.11-05-2009
20090274712COMPOSITIONS FOR COATING CELL MEMBRANES AND METHODS OF USE THEREOF - In certain aspects, the invention relates to cell delivery compositions comprising a progenitor cell and a targeting moiety, and methods related thereto. Such compositions and methods may be used, for example, in administering a targeted cell therapy cell therapy to a subject.11-05-2009
20080311132Human Complement C3 Derivates with Cobra Venom Factor-Like Function - A modified human complement C3 protein (C3) is disclosed comprising a substitution of a portion of a human C3 protein, with a corresponding portion of a Cobra Venom Factor protein (CVF) which results in a human C3 protein with CVF functions, but with substantially reduced immunogenicity. Advantageously, the C3 protein can be manipulated to contain at least one of the following CVF functions: increased stability of the C3 convertase and increased resistance to the actions of factors H and/or I. A large number of hybrid C3 proteins containing substitutions in the C-terminal portion of the alpha chain of C3 are presented and tested for the above functions. Methods of treatment of diseases such as reperfusion injury, autoimmune diseases, and other diseases of increased complement activation are presented as well as methods of increasing the effectiveness of gene therapeutics and other therapeutics.12-18-2008
20090285839Antigen uptake receptor for candida albicans on dendritic cells - Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen 11-19-2009
20110200623POLYPEPTIDE COMPLEX COMPRISING NON-PEPTIDYL POLYMER HAVING THREE FUNCTIONAL ENDS - Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.08-18-2011
20100129383BIFUNCTIONAL FUSION MOLECULES FOR THE DELIVERY OF ANTIGENS TO PROFESSIONAL ANTIGEN-PRESENTING CELLS - The invention provides a bifunctional fusion molecule comprising: a first functional domain comprising a first immunoglobulin variable region, a second immunoglobulin variable region and a linker for connecting the first and second variable regions; a second functional domain comprising a moiety for binding to an antigenic agent; wherein the first and second functional domains are linked; and wherein the first functional domain specifically binds to a surface molecule of a professional antigen-presenting cell, and uses thereof.05-27-2010
20100062006Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer - The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types. 03-11-2010
20080241170Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells - The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.10-02-2008
20100291114Crystal structures and methods using same - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the identification and uses of said modulators.11-18-2010
20100129384TACI-IMMUNOGLOBULIN FUSION PROTEINS - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.05-27-2010
20080292646RECOMBINANT FUSION PROTEIN AND POLYNUCLEOTIDE CONSTRUCT FOR IMMUNOTOXIN PRODUCTION - The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of 11-27-2008
20080292645Antibody or Antibody Fragment Coupled with an Immunogenic Agent - An immunogenic conjugate includes a target cell-specific circulating molecule and at least one immunogenic agent, the immunogenic agent being coupled by any appropriate means with the circulating molecule. Also described is a method for preparing the immunogenic conjugate and its use for treating cancers or autoimmune diseases.11-27-2008
20080311133METHODS OF USING MULTIVALENT MHC CLASS II-PEPTIDE CHIMERAS - The present invention provides a multimeric complex of at least two chimeric molecules, wherein the chimeric molecules comprise an immunoglobulin constant region element and two MHC elements wherein each MHC element is associated with a peptide, and wherein the chimeric molecules are covalently linked through a carbohydrate residue of the immunoglobulin constant region element by a polyalkylene glycol linker. Methods of making and using the multimeric complexes are also provided.12-18-2008
20080311134CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES - Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I:12-18-2008
20080248052Multi-Drug Ligand Conjugates - Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of cytotoxic drugs and vitamin receptor binding ligands. The plurality of drugs may be the same or different. Similarly, the vitamin receptor binding ligands may be the same or different. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers.10-09-2008
20080220005Comb Polymers - The present invention provides a process for producing a comb polymer comprising the steps of: a) providing: (i) (w+z) molar equivalents of a monomer; (ii) one molar equivalent of an initiator compound of formula (IX), wherein B09-11-2008
20110008373PRODRUGS OF CC-1065 ANALOGS - Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.01-13-2011
20100143387MULTIMERIC CONJUGATE - The present invention is directed to a multimeric agent and a multimeric conjugate formed from this multimeric agent and a biologically active agent. Said multimeric conjugates have a longer life time in vivo and an increased avidity compared to the unmodified biologically agent. The present invention is further directed to a pharmaceutical or diagnostic composition containing said conjugate as well as to a method of its production. The invention additionally provides the use of said conjugates for the detection, determination, separation and/or isolation of a specific binding partner and for the diagnosis, prophylaxis and treatment of diseases in which the specific binding partner is directly or indirectly involved.06-10-2010
20080267980Complement Receptor 2 Targeted Complement Modulators - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.10-30-2008
20100136032TRIMERIC OX40-IMMUNOGLOBULIN FUSION PROTEIN AND METHODS OF USE - Compositions including a trimeric OX-40 fusion protein are disclosed. Also disclosed are methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells involving administering to the mammal a composition comprising a trimeric OX-40 fusion protein and a pharmaceutically acceptable carrier.06-03-2010
20100209441DRUG FOR SUPPRESSING PATHOGEN OCCURRING IN VIVO - To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo.08-19-2010
20090304718Antibody Molecules Specific for Fibroblast Activation Protein and Immunoconjugates Containing Them - Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy.12-10-2009
20110206705B7-H3 AS A BIOMARKER FOR DIAGNOSING THE PROGRESSION AND EARLY LYMPH NODE METASTASIS OF CANCER - B7H3 is a ligand member of the immunoregulatory family of proteins on immune cells. In one embodiment, a method for diagnosing the progression of cancer with a high propensity of primary tumor metastasis to the lymph node or distant site is provided. Such a method may comprise obtaining a cancer tissue sample from a cancer patient, determining an expression level of B7-H3 present in the tissue sample, and diagnosing the progression of the cancer having a high propensity of primary tumor metastasis to the lymph node or distant site based upon the expression level, wherein an increased expression level correlates with an increased probability of having regional lymph nodes or organ site that are positive for metastases.08-25-2011
20110206704Methods and compositions for modulating hepatocyte growth factor activator - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of hepatocyte growth factor activator function, and the identification and uses of said modulators.08-25-2011
20090028881Conjugate of an antibody against CCR5 and an antifusogenic peptide - The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate.01-29-2009
20090028882Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof - This invention provides a method of inhibiting the binding of beta-sheet fibril to RAGE on the surface of a cell which comprises contacting the cell with a binding-inhibiting amount of a compound capable of inhibiting binding of beta-sheet fibril to RAGE so as to thereby inhibit binding of beta-sheet fibril to RAGE.01-29-2009
20120183567PROCESS FOR PRODUCING WATER-SOLUBLE HYALURONIC ACID MODIFICATION - The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.07-19-2012
20090136525Immunoglobulins Comprising Predominantly a Glcnacman3Glcnac2 Glycoform - Compositions and methods for producing compositions comprising immunoglobulins or immunoglobulin fragments having an N-linked glycosylation pattern consisting predominantly of the GlCNAcMan05-28-2009
20080317766Costimulatory Molecules and Uses Thereof - The invention relates to a novel costimulatory pathway mediated by a member of the semaphorin protein family, Sema4A, which is selectively expressed on the surface of dendritic cells. In addition, the invention relates to the use of Sema4A protein and protein derivatives in a method for the identification of immunomodulatory substances and to therapeutic applications making use thereof.12-25-2008
20100003266TARGETED IMMUNE CONJUGATES - Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of immunogens to the reticuloendothelial system via non-circulating lymphoid cells are provided.01-07-2010
20080317765Method for Removal of Toxins from Mucosal Membranes - The present invention provides novel mucoadhesive compounds useful in the prevention of diseases and disorders of or which arc associated with the mucosal membrane.12-25-2008
20110223184DKK2 PROTEIN AND USE THEREOF - The present invention provides DKK2 and DKK-Fc fusion protein with angiogesis promoting activity and methods of using the same.09-15-2011
20130122022SEQUENCE OF STRO-1 ANTIBODY VARIABLE REGION - The amino acid sequence of the heavy chain polypeptide and the light chain polypeptide of the STRO-1 antibody is disclosed. Also disclosed are methods for detecting and isolating cells expressing the STRO-1 cell surface protein.05-16-2013
20130122023NOVEL LONG-ACTING GLUCAGON CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR THE PREVENTION AND TREATMENT OF OBESITY - Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.05-16-2013
20110223183HUMAN NOTCH3 BASED FUSION PROTEINS AS DECOY INHIBITORS OF NOTCH3 SIGNALING - This invention provides a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 12 to 34, and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.09-15-2011
20090324620CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES - The invention features conjugates of therapeutic or cytotoxic agents and biologically active peptides and methods of use thereof.12-31-2009
20090324618NOVEL SIGNATURE SELF RENEWAL GENE EXPRESSION PROGRAMS - The present invention relates to compounds and methods which are useful in molecular investigations of target genes, as well as their encoded RNAs and protein, belonging to signature self renewal programs in leukemia and/or cancer stem cells. Data herein shows that leukemia stem cells can be generated from committed progenitors without widespread reprogramming of gene expression, and wherein a leukemia self-renewal associated signature is activated in the process.12-31-2009
20090022742COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS - Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more 01-22-2009
20090081242METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES - Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.03-26-2009
20090053247BIOLOGICAL MATERIALS AND USES THEREOF02-26-2009
20110223185CHIMERIC HEPATITIS C VIRUS ANTIGENS FOR ELICITING AN IMMUNE RESPONSE - Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HVC core, envelope, or non-structural protein fragments) and a target binding domain (an Fc fragment). By virtue of the target binding domain, antigen presenting cells internalize and process the chimeric antigens for antigen presentation, thereby eliciting both a humoral and cellular immune response.09-15-2011
20110229497Modulating the Alternative Complement Pathway - Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.09-22-2011
20090226465MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS - The present invention relates to antibody-drug conjugate compounds of Formula I: Ab (L D)p I where one or more macrocyclic depsipeptide drug moieties (D), selected from Aplidin, Didemnin B, Kahalalide F, and analogs and derivatives therefrom, are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.09-10-2009
20110142859ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR - Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.06-16-2011
20080260756Peptide Inhibitors of iASPP - The invention relates to a polypeptide or part thereof which inhibits the apoptotic activity of the tumor suppressor protein p53, and includes screening methods to identify agents which interfere with the activity of the polypeptide.10-23-2008
20080260755Proteolytically cleavable fusion proteins with high molar specific activity - The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.10-23-2008
20090098148HIGH EFFICIENCY TISSUE-SPECIFIC COMPOUND DELIVERY SYSTEM USING STREPTAVADIN-PROTEIN A FUSION PROTEIN - The present invention relates to methods and compositions that can be employed to introduce toxins and nucleic acids into the cytoplasm or nucleus of a eukaryotic cell, particularly a cell of a higher vertebrate. The invention particularly concerns the use of a fusion protein of streptavidin and protein A sequences to form a non-covalent complex of a toxin or nucleic acid and an antibody.04-16-2009
20090252749Compositions and Methods for Producing a Composition - The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.10-08-2009
20100183633INTERLEUKIN 6 AND TUMOR NECROSIS FACTOR ALPHA AS BIOMARKERS OF JNK INHIBITION - Biomarkers for JNK inhibition are described that can be used for monitoring effectiveness of JNK inhibitors and monitoring treatment with JNK inhibitors.07-22-2010
20090117134Truncated EGF Receptor - The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF1. The present invention also relates to methods of screening for EGF receptor ligands and methods of treatment which involve the use of these molecules.05-07-2009
20100183634MULTIFUNCTIONAL NUCLEIC ACID NANO-STRUCTURES - Compositions and methods are provided for constructing multi-functional nucleic acid nano-structures. Nano-structures are provided incorporating a built-in modularity, including nucleic acid modules. Modules contain moieties including detectible labels, nanoparticles, reactive moieties and other functional groups. Nano-structures can be used for delivery of target compounds, as well as identification of target nucleic acid molecules.07-22-2010
20100189726LPAAT-BETA INHIBITORS AND USES THEREOF - The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.07-29-2010
20080299139MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS - Nucleic acids encoding mammalian, e.g., primate, IL-1ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.12-04-2008
20110129484IMMUNOTHERAPIES EMPLOYING SELF-ASSEMBLING VACCINES - Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical.06-02-2011
20100183635GLYCOSYLATED SPECIFICITY EXCHANGERS - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.07-22-2010
20110059115ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.03-10-2011
20100015166Therapeutic antibodies - A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.01-21-2010
20110236403TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.09-29-2011
20080311135IMMUNE COMPLEX VACCINATION AS A STRATEGY TO ENHANCE IMMUNITY IN THE ELDERLY AND OTHER IMMUNE COMPROMISED POPULATIONS - The present invention generally concerns methods and compositions for improving the immune system of an individual that is an immune-compromised individual. In particular aspects, the immune-compromised individual is elderly or is immunosuppressed, such as from chemotherapy or immunosuppressants following organ or tissue transplantation. In specific embodiments, the invention relates to delivery to the immune-compromised individual of immune complexes harboring an antigen and an antibody that immunologically recognizes the antigen. The antigen may be viral, bacterial, or fungal, for example.12-18-2008
20130129752TARGETED DELIVERY TO LEUKOCYTES USING PROTEIN CARRIERS - Disclosed herein are is a leukocyte-selective delivery agent comprising, a targeting moiety that selectively binds LFA-I, a protein carrier moiety covalently linked to the targeting moiety, and a therapeutic agent associated with the carrier moiety. The delivery agent may be further selective for activated leukocytes, wherein the targeting moiety selectively binds LFA-I in its activated conformation. The targeting moiety comprises an antibody or functional fragment thereof, such as an scFV. Examples of antibodies or fragments thereof which selectively bind LFA-I activated conformation bind to the locked open I domain of LFA-I, or binds to the leg domain of the β2 subunit of LFA-I ((ILP2)—The antibody or functional fragment thereof may alternatively bind non-selectively to both low affinity and high affinity LFA-I. Examples of a non-protein carrier are a basic polypeptide such as protamine or a functional fragment thereof. One such fragment is RSQSRSRYYRQRQRSRRRRRRS. The therapeutic agent may comprise one or more of a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. An example of a nucleic acid delivery agent comprises an RNA interference molecule. Examples of RNA interference molecules are siRNA, dsRNA, StRNA, shRNA, miRNA, and combinations thereof. Specific siRNAs are provided. Other examples of a nucleic acid delivery agent are a small RNA, an antagomir, an LNA, and an antisense oligonucleotide. Methods for leukocyte-selective delivery, or activated leukocyte-selective delivery in vivo, in vitro and ex vivo are also provided.05-23-2013
20110117114Neovascular-Targeted Immunoconjugates - Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.05-19-2011
20100310584Antigen - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.12-09-2010
20100303835PEPTOID LIGANDS FOR ISOLATION AND TREATMENT OF AUTOIMMUNE T-CELLS - The present invention provides for the identification of autoreactive T cell populations from individuals having autoimmune diseases, such as multiple sclerosis and EAE. Peptoids recognized by autoreactive T cells can be used to identify various types of autoimmune disease, and can also be used to target therapies against such populations.12-02-2010
20130136756ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS - Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.05-30-2013
20090214576TYROSINE KINASE INHIBITOR COMPOSITIONS AND METHODS FOR MANUFACTURING AND USING THEM IN THE TREATMENT OF DISEASE - The invention is the method of using the soluble modified receptor erbB3 to treat breast cancer by competitively inhibiting ligands, such as heregulin, from binding to erbB3 tyrosine kinase receptors on cell surfaces.08-27-2009
20090068203Methods for treating cardiovascular disease using a soluble CTLA4 Molecule - The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.03-12-2009
20090117133POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW AFFINITY FCyRECEPTORS - The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG05-07-2009
20110243967MOLECULAR COMPLEXES WHICH MODIFY IMMUNE RESPONSES - Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.10-06-2011
20110243966SINGLE CHAIN Fc (ScFc) REGIONS, BINDING POLYPEPTIDES COMPRISING SAME, AND METHODS RELATED THERETO - The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject.10-06-2011
20110064751TARGETED IMMUNOCONJUGATES - The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.03-17-2011
20110086050GLYCOPROTEIN COMPOSITIONS - The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.04-14-2011
20100015164Compositions and Methods for Modulating Osteoblast Cell Differentiation and Bone Generation Through HIF-1a - The present invention provides a novel screening tool for the determination of compounds capable of promoting bone healing, promoting osteoblast cellular differentiation, improving bone mass or volume, and/or promoting osteogenesis that could be used in the treatment of various bone-loss or bone density decreasing disorders. The present invention also provides a screening tool for the determination of compounds capable of inhibiting osteoblast cellular differentiation, decreasing bone mass or volume, and/or inhibiting osteogenesis. Also provided are compositions and methods for the treatment of various bone-loss or bone density decreasing disorders.01-21-2010
20100008937TARGETED DELIVERY TO LEUKOCYTES USING NON-PROTEIN CARRIERS - Disclosed are delivery agents for selective delivery to leukocytes. The leukocyte-selective delivery agents comprise a targeting moiety that selectively binds LFA-I, a non-protein carrier moiety covalently linked to the targeting moiety and a therapeutic agent associated with the carrier moiety. The non-protein carrier moiety comprises a liposome, a micelle, or a polymeric nanoparticle comprised of PLA or PLGA. The delivery agent may be further selective for activated leukocytes by using a targeting moiety that selectively binds LFA-I in its activated conformation. The targeting moiety may comprise an antibody or functional fragment thereof such as an scFV. Appropriate therapeutic agents include a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. Additional examples of therapeutic agents are a small RNA, an antagomir, an LNA, or an antisense oligonucleotide. One such therapeutic agent is an RNA interference molecule such as siRNA, dsRNA, stRNA, shRNA, miRNA. Specific delivery agents are provided. Methods for in vivo, in vitro and ex vivo leukocyte-selective delivery using the delivery agents are also disclosed.01-14-2010
20090028884OLIGOMERIC RECEPTOR LIGAND PAIR MEMBER COMPLEXES - This invention concerns an oligomeric receptor-ligand pair member complex which includes (i) an oligomeric core, said core comprising at least two chimeric proteins, said chimeric proteins comprising a first section including at least one domain forming part of a first member of a complementary binding pair and a second section comprising an oligomerising domain derived from an oligomer-forming coiled-coil protein, wherein formation of the oligomeric core occurs by oligomerisation at the oligomerising domain of the chimeric proteins; and (ii) at least two receptor-ligand pair member peptides derived from a receptor-ligand pair member peptide chain or a functional part thereof, wherein each receptor-ligand pair member peptide further comprises attached thereto a second member of said complementary binding pair capable of binding to the first complementary binding pair member as defined in (i). Each receptor-ligand pair member peptide is bound to the core via binding of the first and second members of the complementary binding pair. At least two of the receptor-ligand pair member peptides in the complex are derived from the same receptor-ligand pair member peptide chain. In one embodiment, the oligomerising domain in the second section in at least one of the chimeric proteins is derived from the pentamerisation domain of the human cartilage oligomeric matrix protein (COMP). The invention further concerns related pharmaceutical and diagnostic compositions and processes.01-29-2009
20120148609INTRACORONARY DEVICE AND METHOD OF USE THEREOF - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems.06-14-2012
20080254045Modulation of NKT Cell Activity with Antigen-Loaded CD1d Molecules - The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.10-16-2008
20100260785SARP-1 Fusion Proteins and Uses Thereof - The invention relates to a fusion protein comprising a mature SARP-1 polypeptide without the Netrindomain, the fusion protein further comprising an Fc region of an immunoglobulin, wherein the fusion protein lacks certain N-terminal amino acids of the mature SARP-1 polypeptide. The invention further relates to the use of said fusion protein for treating cancer, a fibrotic disorder or a cardiovascular disorder.10-14-2010
20110150907METHODS AND MATERIALS FOR GASTROINTESTINAL DELIVERY OF PATHOGEN/TOXIN BINDING AGENTS - The present disclosure relates generally to recombinant bacteria (e.g., 06-23-2011
20110250215STRUCTURALLY-RELATED RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES - Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion proteins may include a linker portion or other sections as well. Suitable fusion proteins are also those predicted to have the same effect as human relaxin in vivo, based, for example, on structural modeling. The fusion protein is useful in the treatment of a number of diseases and conditions, including heart disease, vascular disease, wound healing, fibrosis, fibromyalgia, and promoting angiogenesis.10-13-2011
20090022744Modified Fc molecules - The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.01-22-2009
20090022743Peptides Effective in the Treatment of Tumors and Other Conditions Requiring the Removal or Destruction of Cells - The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.01-22-2009
20080248050Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine - A meta-specific vaccine particle is provided. Also provided is a method for inducing an immune response in a human (10-09-2008
20090280132COUPLING OF PERIPHERAL TOLERANCE TO ENDOGENOUS IL-10 PROMOTES EFFECTIVE MODULATION OF T CELLS AND AMELIORATES AUTOIMMUNE DISEASE - Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor agonist or antagonist. The compounds and compositions of the invention may be used to selectively suppress the immune system to treat symptoms associated with immune disorders such as allergies, transplanted tissue rejection and autoimmune disorders including autoimmune diabetes, rheumatoid arthritis and multiple sclerosis.11-12-2009
20110212114METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS - Provided herein are methods and kits for making a targeted therapeutic for treating a disease or condition. The therapeutic agents can be targeted to patient-specific disease markers. In one of these methods, the method includes obtaining a biological sample from a patient having the disease or condition, or who is at risk for developing the disease or condition. In this particular method, the sample includes a population of diseased cells, screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. Some of the methods further include preparing a library with proteins linked to their cognate mRNAs. In certain of these methods, the preparation of the library includes providing at least two candidate mRNA molecules in which each of the mRNA molecules includes a cross-linker, translating at least two of the candidate mRNA molecules to generate at least one translated protein, and linking at least one of the candidate mRNA molecules to its corresponding translated protein via the cross-linker to form at least one cognate pair.09-01-2011
20110256156TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.10-20-2011
20080220004Use of VEGF inhibitors for treatment of eye disorders - Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.09-11-2008
20080220002MODIFIED TRANSFERIN-ANTIBODY FUSION PROTEINS - Modified fission proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.09-11-2008
20090285840METHODS FOR TREATING PATHOLOGICAL NEOVASCULARIZATION - Provided herein are compositions and methods that inhibit expression of Adam9 gene products, such as ADAM9 mRNA and/or ADAM9 polypeptides, as a therapeutic approach for the treatment of pathological neovascularization and conditions associated with angiogenesis.11-19-2009
20120231022GLP-1 RECEPTOR AGONIST COMPOUNDS FOR SLEEP ENHANCEMENT - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to enhance sleep, increase the duration and/or intensity of non-rapid eye movement (NREM) sleep, treat NREM sleep disorders, and to treat circadian rhythm sleep disorders. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs (e.g., GLP-1(7-36)-NH09-13-2012
20110165182CONJUGATE OF AN ANTIBODY AGAINST CCR5 AND AN ANTIFUSOGENIC PEPTIDE - The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate.07-07-2011
20110165181RELAY VACCINE - The present invention provides a method and composition for raising an immune response in an animal. The method comprising administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety. The targeting moiety binds to at least one receptor that is upregulated on lymphocytes that home to MAdCAM07-07-2011
20110020371POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY - The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.01-27-2011
20110097345NOVEL DOSING REGIMEN AND METHOD OF TREATMENT - This invention relates to a method of treatment and dosing regimen for treating disease, such as cancer and mammalian tumors, wherein therapy with a cytotoxic drug is suitable, by the administration of an antibody-toxin conjugate, such as a maytansinoid toxin, by infusion at an initial infusion rate of 1 mg/min or lower on a schedule selected from the group consisting of: (1) an amount of at least about 90 mg/m04-28-2011
20080233135Cobalamin taxane bioconjugates - The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.09-25-2008
20100330107ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS - Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.12-30-2010
20110135667ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.06-09-2011
20110052611PEPTIDE CONJUGATE COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.03-03-2011
20110052610ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.03-03-2011
20110052609MAGNETIC TRANSDUCERS - Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.03-03-2011
20090053246IMMUNOGLOBULIN FC FRAGMENT MODIFIED BY NON-PEPTIDE POLYMER AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are an Fc fragment modified by a non-peptide polymer, a pharmaceutical composition comprising the Fc fragment modified by the non-peptide polymer as a carrier, a complex of the Fc fragment and a drug via a linker and a pharmaceutical composition comprising such a complex. The Fc fragment modified by a non-peptide peptide according to the present invention lacks immunogenicity and effector functions. Due to these properties, the Fc fragment maintains the in vivo activity of a drug conjugated thereto in high levels, remarkably increases the serum half-life of the drug, and remarkably reduces the risk of inducing immune responses.02-26-2009
20110177100TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.07-21-2011
20100158928IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS - The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety.06-24-2010
20100196404METHODS OF USE OF THE TACI/TACI-L INTERACTION - The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.08-05-2010
20100196403ANTIBODY CONJUGATES FOR CIRCUMVENTING MULTI-DRUG RESISTANCE - Conjugates of a cell permeability moiety coupled to an antibody against an intracellular epitope of a multi drug resistance (MDR) protein are provided. Also provided are pharmaceutical compositions that include these conjugates and methods for their use in preventing and inhibiting multi drug resistance to therapeutic agents, particularly to chemotherapeutic agents.08-05-2010
20100068215Use of GDF traps to increase red blood cell levels - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.03-18-2010
20090202572COMPOSITIONS AND METHODS FOR MODULATING BONE MASS - The instant invention relates to compositions and methods for treating or preventing bone diseases. In certain aspects, the invention provides compositions comprising a β-adrenergic antagonist or agonist associated to a bone-targeted molecule, as well as methods of modulating bone mass and/or growth in a mammal by administering a composition of the present invention. In other aspects, the invention provides methods of modulating bone mass and/or growth in a mammal by administering a composition comprising a β2-selective antagonist or agonist.08-13-2009
20090175887ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.07-09-2009
20090175886MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUES - The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the growth of CD30 cells, such as tumor cells, are also provided.07-09-2009
20110189208TB VACCINE - The invention relates to a vaccine useful in therapy and prevention of mycobacterial infections.08-04-2011
20100189727Masking Ligands For Reversible Inhibition Of Multivalent Compounds - Masking ligands for reversibly concealing the antigen-binding site of an antibody comprise epitopes of the antibody and a cleavable linker. Methods for making masking ligands comprise joining at least two copies of the epitope of an antibody to a cleavable polypeptide linker.07-29-2010
20110189207METHODS FOR SOLUBLE ZALPHA11 CYTOKINE RECEPTORS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.08-04-2011
20110189206Antibody Targeting Through a Modular Recognition Domain - Antibodies containing one or more modular recognition domains (MRDs) used to target the antibodies to specific sites are described. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.08-04-2011
20110177101TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.07-21-2011
20120064098Intracoronary Device And Method Of Use Thereof - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems.03-15-2012
20100028369Hazardous substance removing material and method for removing hazardous substance - It is an object of the present invention to provide a hazardous substance removing material, which efficiently captures hazardous substances derived from microorganisms such as bacteria or viruses and rapidly inactivates them, so as to minimize the their influences on human bodies, and which is able to allow an antibody to be supported on a carrier by a simple method, and which has an improved antibody use efficiency. The present invention provides a hazardous substance removing material consisting of a carrier on which an antibody and a polymer material having an affinity for Fc region of the antibody are supported.02-04-2010
20100028366SYNERGISTIC EFFECT BETWEEN A CYANOGENIC SYSTEM AND ANOTHER OXIDATIVE INDUCING SYSTEM FOR TREATING TUMORS - The invention relates to a system capable of causing the death of tumor cells by activating caspase-independent apoptosis, comprising: 02-04-2010
20120308583USE OF GCC LIGANDS - Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed.12-06-2012
20100021481CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY - Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.01-28-2010
20100021482NOVEL DEATH ASSOCIATED PROTEINS, AND THAP1 AND PAR4 PATHWAYS IN APOPTOSIS CONTROL - The invention relates to genes and proteins of the THAP (THanatos (death)-Associated Protein) family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to the Par4 protein and SLC chemokine pathways, including the interaction of Par4 and SLC with THAP family proteins, and the recruitment and localization of Par4 to PML nuclear bodies.01-28-2010
20100028368SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF - Compounds useful as antiproliferative agents according to formula (I): wherein Ar02-04-2010
20110076287NEMORUBICIN METABOLITE AND ANALOG REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS - The present invention relates to antibody-drug conjugate compounds of Formula I:03-31-2011
20100215670Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers - Novel conjugates are disclosed which comprise (a) a ligand that binds to a surface molecule on a target cell, such as a cancer cell; (b) an effector molecule that is to be delivered into the cell, such as a toxin; and (c) a linker sequence that couples the ligand and the effector molecule wherein the linker comprises at least one protease cleavage site corresponding to a protease found in the intracellular trafficking pathway of the effector molecule; wherein the cleavage of the linker by the protease uncouples the effector molecule from the ligand.08-26-2010
20080299136WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.12-04-2008
20090104210Peptide compounds for treating obesity and insulin resistance - Compounds comprising an angiopoietin-like protein 6 (Angptl6) peptide for use in the treatment of metabolic syndrome, in particular, obesity and insulin resistance are described.04-23-2009
20110305716TARGETED CYTOKINE FOR TREATMENT OF DISEASES - Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a TGF-beta associated with immunoglobulins (such as IgGs) or functional portions thereof including Fc portions, such as by non-covalent bonds. The provided complexes include those in which the immunoglobulin portion binds to inhibitory Fcγ receptors to a greater degree than to activating Fcγ receptors. The provided complexes further include those in which the immunoglobulin portion bind to activating Fcγ receptors to a greater degree than to inhibitory Fcγ receptors. The complexes and compositions can be used for administration to subjects, such as for increasing immunity or decreasing inflammation, such as for treating diseases including autoimmune diseases and cancer.12-15-2011
20110070249IMMUNIZING COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST THE Beta-SECRETASE CLEAVAGE SITE OF AMYLOID PRECURSOR PROTEIN - The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AβPP epitope spanning the β-secretase cleavage site of AβPP and a method for inducing an immune response against the β-secretase cleavage site of AβPP using this immunizing composition. The present invention is also directed to antibodies against the β-secretase cleavage site of AβPP and their use in a method for inhibiting the formation of amyloid β.03-24-2011
20100196405GLP-1 Fc FUSION PROTEIN FORMULATION - The invention provides a stable solution formulation comprising a therapeutically effective amount of a GLP-1-Fc fusion protein at about pH 6.5 in citrate buffer with polysorbate-80 and mannitol. The formulation is useful in treating diabetes and obesity as well as a variety of other conditions or disorders.08-05-2010
20110070248DR5 LIGAND DRUG CONJUGATES - Ligand Drug Conjugates are provided having a DR5 binding moiety attached via linking groups and/or spacers to a therapeutic agent and are effective in treatment of various cancers.03-24-2011
20080220003C5a Receptor Antagonists - The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are individually and independently selected from the group comprising H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, alkoxyl, substituted alkoxyl, aryloxy, substituted aryloxy, arylalkyloxy, substituted arylalkyloxy, acyloxy, substituted acyloxy, halogen, hydroxyl, nitro, cyano, acyl, substituted acyl, mercapto, alkylthio, substituted alkylthio, amino, substituted amino, alkylamino, substituted alkylamino, bisalkyl amino, substituted bisalkyl amino, cyclic amino, substituted cyclic amino, carbamoyl (—CONH09-11-2008
20110064753DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE - Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.03-17-2011
20110064750METHOD AND KIT FOR TREATING NICOTINE ADDICTION - Described are methods and kits related to treating nicotine addiction and increasing the likelihood of nicotine abstinence. Methods and kits for reestablishing nicotine abstinence after a relapse to nicotine use are also described.03-17-2011
20110064754Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines - The present invention concerns methods and compositions for subunit-based vaccines for inducing immunity against poxvirus infections, such as smallpox. Preferred embodiments concern immunoconjugates comprising one or more subunit antigenic peptides attached to an antibody or fragment thereof that targets antigen-producing cells (APCs). More preferably, the antibody binds to HLA-DR and the antigenic peptide is from an immunomodulating factor, such as the viral IL-18 binding protein (vIL18BP). However, mixtures of antigenic peptides from different viral proteins may also be used. The vaccine is capable of inducing immunity against poxvirus without risk of disseminated infection in immunocompromised hosts or transmission to susceptible contacts.03-17-2011
20110064752EXTRACELLULAR TARGETED DRUG CONJUGATES - The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.03-17-2011
20120156227PROTEINS MODIFIED WITH (AMINO) MONOSACCHARIDE-BIOTIN ADDUCT - A protein covalently linked to, or coated with, a non-immunogenic molecule selected from an amino monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immuno-genicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination06-21-2012
20100021480BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME - This invention relates to a technology of modifying low-molecular-weight bioactive substances with short in vivo half-life and low stability in order to achieve a stable and efficient in vivo delivery thereof. More specifically, the present invention relates to a stable bioactive substance-blood protein conjugate, wherein a low-molecular-weight bioactive substance is ex vivo conjugated with a specific functional group on a blood protein through a reactive group, the low-molecular-weight bioactive substance is available as a drug for treatment and prevention in mammals including human and selected from the group consisting of a natural substance; and a method of a stable and efficient in vivo delivery of the low-molecular-weight bioactive substance based on the use of the bioactive substance-blood protein conjugate.01-28-2010
20110318371Novel serpentine transmembrane antigens expressed in human cancers and uses thereof - Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.12-29-2011
20110318370CXCL4L1 AS A BIOMARKER OF PANCREATIC CANCER - The invention relates to the use of CXCL4L1 as a biomarker of pancreatic cancer in a patient. More particularly, the invention relates to a method for detecting a pancreatic cancer and/or pancreatic metastasis in a patient, said method comprising determining the expression level of the CXCL4L1 gene in a biological sample obtained from said patient.12-29-2011
20090068205ErbB4 antagonists - The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing the proliferation or migration of smooth muscle cells.03-12-2009
20120009205Modified Fc Molecules - Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.01-12-2012
20090252750ANTIBODIES AND IMMUNOTOXINS THAT TARGET HUMAN GLYCOPROTEIN NMB - The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.10-08-2009
20120114673COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same.05-10-2012
20120058131PTA089 PROTEIN - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer treatment, and for drug development.03-08-2012
20120064097Enhanced Binding of Pro-Inflammatory Cytokines by Polysaccharide-Antibody Conjugates - We provide monoclonal antibodies against interleukin-1β and tumor necrosis factor-α that remain biologically active in vitro when conjugated to high molecular weight polysaccharides. We report enhanced binding of these cytokines when their monoclonal antibodies are conjugated to alginate compared to non-conjugated monoclonal antibodies. In cell assays, polysaccharide-antibody constructs of the invention inhibited cytokine signaling to comparable levels as that of unmodified antibodies. Conjugation of cytokine-neutralizing antibodies to high molecular weight polymers enhances the affinities cytokine-binding moieties used as anti-inflammatory therapeutics.03-15-2012
20120282280BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES - This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical 5 compositions containing said antibodies, and uses thereof.11-08-2012
20110104184ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS OF USE THEREOF - Disclosed are antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Also disclosed are methods of using such antibodies to reduce cancer cell tissue factor activity and to detect cancer cells that express TF.05-05-2011
20110104185ANTIBODY FRAGMENT-POLYMER CONJUGATES AND USES OF SAME - Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α05-05-2011
20120251557GalNAc-SPECIFIC BINDING MOLECULES AND USES THEREOF - The present invention provides, among others, means and methods for detecting terminal GalNAc-containing molecules. A preferred molecule for detecting the structures is a molecule comprising a carbohydrate binding part of MGL.10-04-2012
20120121614METHODS AND COMPOSITIONS FOR BI-SPECIFIC TARGETING OF CD19/CD22 - Methods and composition involving genetically engineered targeting conjugates with reversed orientation of VL and VH chains are provided. For example, in certain aspects targeting conjugates comprising VL and VH chains of anti-CD22 and anti-CD19 are described. In a further aspect, the invention provides methods and targeting conjugates comprising therapeutic agents or diagnostic agents for delivery to B cells.05-17-2012
20120121613PROTEIN CONJUGATE HAVING AN ENDOPEPTIDASE- CLEAVABLE BIOPROTECTIVE MOIETY - The invention is directed to a procoagulant conjugate having an endopeptidase-activatable procoagulant protein moiety and one or more bioprotective moieties, which are conjugated to one another by a linker that is cleaved by an endopeptidase in situ to release the bioprotective moiety. The invention is also directed to therapeutic uses of the procoagulant conjugate and methods of making the conjugate.05-17-2012
20120315288LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.12-13-2012
20120237532PHARMACEUTICAL FORMULATION CONTAINING IMMUNOGLOBULIN - A set of at least two different protein conjugate preparations, each protein conjugate preparation comprising histidine as a buffering agent and a protein conjugate comprising one or more immunoglobulin moieties conjugated to a carrier protein; wherein the immunoglobulin moieties of each element of said set of protein conjugate preparation have identical complementarity determining regions (CDRs); and wherein different protein conjugate preparations differ in that the immunoglobulin moieties of the protein conjugates have different CDRs.09-20-2012
20120128700CONSTRUCTS FOR DELIVERY OF THERAPEUTIC AGENTS TO NEURONAL CELLS - A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a H05-24-2012
20110182919Immunoglobulin Chimeric Monomer-Dimer Hybrids - The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.07-28-2011
20120135012TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS - Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases.05-31-2012
20100047258Drug Carriers, Their Synthesis, and Methods of Use Thereof - Drug carriers, methods of synthesizing, and methods of use thereof are provided.02-25-2010
20100047259FOLLISTATIN DOMAIN CONTAINING PROTEINS - The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of proteins comprising at least one follistatin domain, excluding follistatin itself, for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration.02-25-2010
20120177667Metal Abstraction Peptide (MAP) Tag and Associated Methods - Compositions comprising a tripeptide having the sequence XC07-12-2012
20100272740MICRO- AND NANOSCALE DEVICES FOR DELIVERY OF ACTIVE FIBRONOLYTIC AGENTS - Disclosed are devices as may be used to deliver a fibrinolytic agent such as functional tPA to targeted sites. Disclosed devices include micro or nanosized particles as carriers of a fibrinolytic agent and a targeting polypeptide such as antifibrin antibody that specifically binds a component of a blood clot. A plurality of protein molecules can be bound to a single particle. In addition, the total number of protein molecules attached to each particle can be controlled as can the proportion of each different compound bound to a single particle. Disclosed devices can be utilized, for example, to deliver tPA to blood clots, for instance in postmyocardial infarction or ischemic stroke treatment, and can minimize systemic plasminemia compared to the use of free tPA.10-28-2010
20090060926MEDICINE FOR TREATMENT OF CARCINOMA - A medicine for treatment of a carcinoma which can be supplied to the carcinoma via the circulatory system, contains two active components coupled to one another. The first active component is formed of at least one coupling molecule that specifically tethers to a target molecule formed by the cancer tissue. The second active component is formed of at least one signal molecule typical to inflammation, or of at least originating molecule encoding such a signal molecule.03-05-2009
20090060925Rage Fusion Proteins and Methods of Use - Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.03-05-2009
20120258124ANTIGEN-ANTIBODY COMPLEXES AS HIV-1 VACCINES - The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic antibody-antigen complexes which are formulated into the vaccines of the present invention.10-11-2012
20120082686Neovascular-Targeted Immunoconjugates - Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.04-05-2012
20120082685Dock-and-Lock (DNL) Constructs for Human Immunodeficiency Virus (HIV) Therapy - The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents.04-05-2012
20120263739ANTI INTEGRIN ANTIBODIES LINKED TO NANOPARTICLES LOADED WITH CHEMOTHERAPEUTIC AGENTS - The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity.10-18-2012
20120263738MULTIPLEX DICER SUBSTRATE RNA INTERFERENCE MOLECULES HAVING JOINING SEQUENCES - The present invention is based, in part, upon the insight that compound DsiRNA agents can be generated using site-specific RNase H-cleavable double-stranded nucleic acid regions to attach, e.g., one DsiRNA moiety to another DsiRNA moiety and/or one DsiRNA moiety to a functional group and/or payload. Because such double-stranded nucleic acid joining sequences are site-specifically RNase H-cleavable, the bifunctional molecule is cleaved into DsiRNAs bearing terminal ends that orient dicer cleavage. Detrimental impacts of administering a single double-stranded nucleic acid RNAi agent of longer than 30-35 nucleotides (e.g., provocation of interferon response) is minimized, as once administered to a subject or RNase H-containing cell, RNase H cleavage produces a shortened, active DsiRNA agent(s). The invention provides bifunctional DsiRNA agents that are joined by double-stranded DNA extension joining sequences, which do not provoke RNase H cleavage.10-18-2012
20110123554USES OF IMMUNOCONJUGATES TARGETING CD138 - Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.05-26-2011
20120231024MONOCLONAL ANTIBODIES AND SINGLE CHAIN ANTIBODY FRAGMENTS AGAINST CELL-SURFACE PROSTATE SPECIFIC MEMBRANE ANTIGEN AS DIAGNOSTIC AND THERAPEUTIC TOOLS FOR PROSTATE CANCER - Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.09-13-2012
20120231023Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells - The present invention includes compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of Toll-Like Receptor (TLR) agonist, more specifically a TLR7 ligand (TLR7L), and a pharmaceutically acceptable carrier, wherein the conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation.09-13-2012
20100028367SGP130/FC DIMERS - Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala02-04-2010
20080299137Fusion Proteins That Bind Effector Lymphocytes And Target Cells - Novel fusion proteins that comprise a first portion that corresponds to an antibody-like protein that is specific for an activating receptor on an effector lymphocyte or a variant thereof and a second portion that corresponds to a portion of a cell membrane protein and that binds to a cell-associated target are provided, as are methods of producing such fusion proteins, uses and methods involving such fusion proteins, and compounds and compositions related to such fusion proteins.12-04-2008
20080299138Toll-Like Receptor 3 Modulators and Uses Thereof - Modulators of TLR3 activity and their use are disclosed.12-04-2008
20110045006LUCA2 and Antibodies That Bind Thereto - The invention provides the identification and characterization of disease and cancer-associated antigen, LUCA2. The invention also provides a family of monoclonal antibodies that bind to antigen LUCA2, methods of diagnosing and treating various human cancers and diseases that express LUCA2.02-24-2011
20120148608MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.06-14-2012
20120269828ANTI-DRUG VACCINES - The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject.10-25-2012
20120269827Compositions and Methods for Treatment of Ovarian, Peritoneal, and Fallopian Tube Cancer - The present invention relates to highly effective anti-cancer drug combinations, pharmaceutical compositions comprising the same, and uses thereof in the treatment of ovarian, peritoneal, or fallopian tube cancer. In particular, the present invention is based on the discovery that the administration of a CD56 antibody linked to a cytotoxic compound (e.g., an immunoconjugate) in combination with a chemotherapeutic agent (in particular a gemcitabine compound, a topotecan compound, and a doxorubicin compound), improves the therapeutic index in the treatment of ovarian, peritoneal, or fallopian tube cancer over and above the additive effects of the anticancer agents used alone. In one embodiment of the invention, combinations of the CD56 antibody, or fragment thereof, linked to a cytotoxic compound plus an additional chemotherapeutic agent have a synergistic effect in the ovarian cancer therapeutic index.10-25-2012
20120269831SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF - Compounds useful as antiproliferative agents according to Formula (I), wherein n, A, R10-25-2012
20120269830CONJUGATES WITH IMPROVED PHARMACOKINETIC PROPERTIES - The present invention concerns methods and means for modulating pharmacokinetic properties of molecules, such as biologically active molecules. More specifically, the present invention concerns conjugates comprising a biologically active moiety and a moiety conjugated to and modulating at least one pharmacokinetic property of the biologically active moiety (pharmacokinetic property modulating moiety).10-25-2012
20100233189Crystal structure - This invention relates to a crystallisable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications.09-16-2010
20110262466COMPOSITIONS CONTAINING THROMBOMODULIN DOMAINS AND USES THEREOF - Compositions are provided comprising a thrombomodulin domain linked to a targeting moiety that binds to a determinant on the surface of a target endothelial cell or red blood cell, wherein the thrombomodulin domain may be the extracellular domain, the N-terminal lectin-like domain, or an epidermal growth factor (EGF)-like domain. The targeting moiety may be a single chain antigen-binding domain (scFv), and the targeting moiety and thrombomodulin domain of the composition may be linked as a continuous polypeptide chain. Methods of delivery and use of a composition described herein are provided, as well as methods of treating or preventing thrombosis, inflammation, tissue ischemia, sepsis, acute lung injury (ALI), acute myocardial infarction (AMI), ischemic stroke, cerebrovascular disease, pulmonary embolism, or ischemic peripheral vascular disease is provided.10-27-2011
20120321647STRUCTURED RNA MOTIFS AND COMPOUNDS AND METHODS FOR THEIR USE - Disclosed are compositions and methods involing riboswitches and RNA motifs. For example, disclosed are compositions and methods involving glutamine-responsive riboswitches, S-adenosylmethionine-repsonsive riboswitches, S-adenosylhomocysteine-repsonsive riboswitches, glutamine riboswitches, SAM/SAH riboswitches, glnA riboswitches, Downstream-peptide riboswitches, crcB riboswitches, pfl riboswitches, yjdF riboswitches, manA riboswitches, wcaG riboswitches, epsC riboswitches, ykkC-III riboswitches, psaA riboswitches, psbA riboswitches, PhotoRC-I riboswitches, PhotoRC-II riboswitches, and psbNH riboswitches.12-20-2012
20120282279Anti-Diabetic Compounds - The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.11-08-2012
20120282281Agents that Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR) - The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.11-08-2012
20120100159ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES - Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided.04-26-2012
20100209440Targeted Delivery of siRNA - The present invention provides a method of delivering RNA interference molecules to a cell or a cell in a subject, which comprises contacting the cell with a protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a protein, the protein comprising (1) a targeting moiety, which will specifically bind to a site on a target cell, and (2) a binding moiety linked thereto, which will bind to the double stranded RNA, wherein the double stranded RNA segment is delivered to a cell and effects RNA interference of the target RNA in the cell.08-19-2010
20130011418Antibody-Drug Conjugates - Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same.01-10-2013
20130017210DISPLAY OF ANTIBODY FRAGMENTS ON VIRUS-LIKE PARTICLES OF RNA BACTERIOPHAGES - The invention enables the display of antibody single-chain variable fragments (scFv's on virus-like particles (VLPs) of bacteriophages such as MS2. The VLPs encapsidate mRNA encoding the coat protein from which it assembles, enabling the recovery by reverse transcription and PGR of affinity-selected sequences from scFv libraries. Related virus-like particles, method for constructing a library of scFv-VLPs, drug delivery vehicles comprising one or more pharmaceutically-active ingredients, biomedical imaging agents, assays, and kits are also provided.01-17-2013
20110159018COMPLEMENT FACTOR H-DERIVED SHORT CONSENSUS REPEAT-ANTIBODY CONSTRUCTS - The present invention relates to a complement activating construct comprising a complement factor H-derived short consensus repeat (fH-derived SCR) and a binding molecule which specifically recognizes a pathogen. More specifically, the fH-derived SCR is selected from the group consisting of SCR7, SCR9, SCR13, SCR18-20 and artificial SCR (aSCR). Furthermore, an in vivo method for screening complement-based approaches for the treatment of the prevention, treatment or amelioration of an infection with a pathogen or a pathological condition associated with an infection with a pathogen is described.06-30-2011
20090317408LIGAND CONJUGATED THERMOTHERAPY SUSCEPTORS AND METHODS FOR PREPARING SAME - Magnetic nanoparticles exhibiting enhanced heating ability in thermotherapeutic applications are described, as are several strategies to conjugate such nanoparticles. Methods for using conjugated nanoparticles are also provided.12-24-2009
20080248051MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.10-09-2008
20080241169IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY - A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, desegregation of plaques results from the immunization.10-02-2008
20080286290Anti-Cd14 Antibody Fusion Protein - A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.11-20-2008
20080226656RG1 antibodies and uses thereof - The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.09-18-2008
20130177580TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.07-11-2013
20130115230DELIVERY PROTEINS - Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of a payload, e.g., an immunogen, to the reticuloendothelial system via non-circulating lymphoid cells are provided.05-09-2013
20130101607Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) Single Chain FV Antibody Fragment Conjugates and Methods of Use Thereof - Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided.04-25-2013
20130101608HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR - Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.04-25-2013
20110217321ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS - Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.09-08-2011
20080199483LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION - Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.08-21-2008
20090028880Serum albumin binding proteins - The present invention relates to amino acid sequences that are capable of binding to serum albumin, which sequences do not significantly reduce or inhibit the binding of serum albumin to FcRn or significantly reduce the half-life of serum albumin. It further relates to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.01-29-2009
20110250214DRUG DELIVERY SYSTEM TOWARD DEMYELINATING LESION AND BIOCHEMICAL MARKER OF DEMYELINATING LESION - It is intended to provide a drug delivery system toward a demyelinating lesion. It is also intended to provide a biochemical marker of a demyelinating lesion. A delivery system for a prophylactic and/or therapeutic agent for a demyelinating disease characterized in that a substance capable of specifically recognizing Contactin is conjugated to an active ingredient of a prophylactic and/or therapeutic agent for a demyelinating disease is provided. Also provided is a method of evaluating and/or differentiating a demyelinating disease, including measuring the expression of Contactin in a body fluid.10-13-2011
20080254044Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody - The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.10-16-2008
20120276125NOVEL IMMUNOCONJUGATES - The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.11-01-2012
20120276124MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY - The invention relates to a compound of formula (I):11-01-2012
20100316656CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE - The invention relates to novel tomaymicine derivatives comprising a linker. It also relates to the conjugate molecules that comprise one or more of said tomaymicine derivatives covalently linked to a cell binding agent through a linking group that is present on the linker of the tomaymycin derivative. It also relates to the preparation of the tomaymicine derivatives and of the conjugate molecules.12-16-2010
20130183323TARGETED ANTIBIOTIC AND ANTIMICROBIAL TREATMENTS FOR PERSONALIZED ADMINISTRATION - A solution for the bottleneck issues in antibiotic treatment is to use novel antibiotic formulas with targeted delivery customized based on the nature of the infection and resistance profile of the infectious agent(s).07-18-2013
20090304719ACTIVATABLE BINDING POLYPEPTIDES AND METHODS OF IDENTIFICATION AND USE THEREOF - The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.12-10-2009
20110311558Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases - Methods, compositions and kits are disclosed for inhibiting interferon production and modulating immune responses, particularly an autoimmune response. In certain embodiments, the methods involve administering an effective amount of a BST2 protein or a nucleic acid encoding an BST2 protein to treat an autoimmune disease or disorder.12-22-2011
20130189286ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS - Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.07-25-2013
20120014974METHODS OF MODULATING CELL DEATH BASED ON THE BIT1/AES REGULATORY PATHWAY - The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that allow the Bit1 polypeptide or active fragment thereof to associate with the AES polypeptide or active fragment thereof; and detecting an altered association of the Bit1 polypeptide or active fragment thereof and the AES polypeptide or active fragment thereof, where an altered association indicates that the agent is an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. Such an effective agent can modulate apoptosis and can be a useful therapeutic agent.01-19-2012
20120027784MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.02-02-2012
20120027783MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.02-02-2012
20120027782MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) - The present disclosure relates to antibody-partner molecule conjugates directed to PTK7. Also described are methods for treating or preventing a disease characterized by growth of tumor cells expressing PTK7 using the antibody-partner molecule conjugates.02-02-2012
20120027781Neuroprotective and neurorestorative method and compositions - The invention relates to methods and products for preventing and treating neuronal cell death-associated diseases and/or conditions. The products and methods are useful for research and for clinical applications relating to neuronal cell-death associated diseases and/or conditions.02-02-2012
20130202625USE OF HUMAN ERYTHROCYTES FOR PREVENTION AND TREATMENT OF CANCER DISSEMINATION AND GROWTH - The technology relates in part to methods of preventing and treating diseases and conditions associated with cancer, including methods, compositions, and kits used for preventing and treating cancer dissemination and growth.08-08-2013
20120070451METHODS AND COMPOSITIONS FOR MODULATING CARDIAC CONTRACTILITY - Provide is a Ca03-22-2012
20120076804CANCER TARGETED INNATE IMMUNITY - Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.03-29-2012
20120093840TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS - The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.04-19-2012
20130209493BIOMAKERS FOR CIRCULATING TUMOR CELLS - Provided are methods for detecting circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.08-15-2013
20130209494ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR - Enediyne compounds having a structure according to formula (I), where R08-15-2013
20130209495ErbB3 ANTIBODIES - Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.08-15-2013

Patent applications in class CONJUGATE OR COMPLEX OF MONOCLONAL OR POLYCLONAL ANTIBODY, IMMUNOGLOBULIN, OR FRAGMENT THEREOF WITH NONIMMUNOGLOBULIN MATERIAL

Patent applications in all subclasses CONJUGATE OR COMPLEX OF MONOCLONAL OR POLYCLONAL ANTIBODY, IMMUNOGLOBULIN, OR FRAGMENT THEREOF WITH NONIMMUNOGLOBULIN MATERIAL